Fate Therapeutics (FATE)
NASDAQ:FATE

Fate Therapeutics (FATE) Income Statement

989 Followers

Fate Therapeutics Income Statement

Last quarter (Q3 2022), Fate Therapeutics's total revenue was $14.98M, an increase of 5.31% from the same quarter last year. In Q3, Fate Therapeutics's net income was $-83.56M. See Fate Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ 69.01M$ 55.85M$ 31.43M$ 10.68M$ 4.74M$ 4.11M
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 382.36M$ 272.84M$ 159.52M$ 111.41M$ 71.83M$ 46.23M
Operating Income
$ -313.35M$ -216.99M$ -128.09M$ -100.73M$ -67.09M$ -42.13M
Net Non Operating Interest Income Expense
$ 3.26M$ 1.31M$ 2.40M$ 2.58M$ 494.00K$ -709.00K
Other Income Expense
$ 16.11M$ 3.53M$ -47.70M--$ -118.00K
Pretax Income
$ -293.98M$ -212.15M$ -173.39M$ -98.15M$ -66.60M$ -42.95M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -293.98M$ -212.15M$ -173.39M$ -98.15M$ -66.60M$ -42.95M
Basic EPS
$ -3.05$ -2.24$ -2.10$ -1.44$ -1.19$ -1.02
Diluted EPS
$ -3.05$ -2.24$ -2.10$ -1.44$ -1.19$ -1.02
Basic Average Shares
$ 385.87M$ 94.75M$ 82.39M$ 68.19M$ 56.20M$ 41.98M
Diluted Average Shares
$ 385.87M$ 94.75M$ 82.39M$ 68.19M$ 56.20M$ 41.98M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 382.36M$ 272.84M$ 159.52M$ 111.41M$ 71.83M$ 46.23M
Net Income From Continuing And Discontinued Operation
$ -293.98M$ -212.15M$ -173.39M$ -98.15M$ -66.60M$ -42.95M
Normalized Income
$ -294.44M$ -215.69M$ -125.69M$ -98.15M$ -66.60M$ -42.83M
Interest Expense
-$ 0.00$ 0.00$ 1.75M$ 1.70M$ 1.27M
EBIT
$ -308.51M$ -212.15M$ -173.39M$ -96.40M$ -64.90M$ -41.68M
EBITDA
$ -297.38M$ -206.30M$ -170.30M$ -94.20M$ -63.70M$ -40.71M
Currency in USD

Fate Therapeutics Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis